2010 article - Effcacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Das
Posted 07 May 2016 - 05:19 AM
Posted 08 May 2016 - 08:00 AM
Good news, but it's an awfully small study. Heck, I think there are more of us on here on reduced dosage then there was in their study. Maybe we should publish!
"You can't change the direction of the wind but you can adjust your sails."
DX 12/08; Gleevec 400mg; liver toxicity; Sprycel 100mg.; CCyR 4/10; MMR 8/10; Pleural Effusion 2/12; Sprycel 50mg. Maintaining MMR; 2/15 PCRU; 8/16 drifting in and out of undetected like a wave meeting the shore. Retired 12/23/2016! 18 months of PCRU, most recent at Mayo on 7/25/17 was negative at their new sensitivity reporting of 0.003.<p>
Posted 08 May 2016 - 03:36 PM
Not a bad option for docs wanting to conduct and report on a trial, particularly with so much anecdotal information here.
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users